Rol' trospiya khlorida (Spazmeks) v lecheniimuzhchin s simptomami giperaktivnogo mochevogo puzyrya i adenomoy predstatel'noy zhelezy
- Authors: Shkol'nikov M.E1, Krivoborodov G.G1, Efremov N.S1
-
Affiliations:
- ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ
- Issue: Vol 14, No 7 (2012)
- Pages: 43-46
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/93669
- ID: 93669
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
M. E Shkol'nikov
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФКафедра урологии
G. G Krivoborodov
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФКафедра урологии
N. S Efremov
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФКафедра урологии
References
- Irwin D.E., Milsom I, Hunskaar S et al. Population - Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. Eur Urol 2006; 50: 1306–15.
- Garraway W.M., Collins G.N., Lee R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71.
- Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub - committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78.
- Michel M.C., Chapple C.R. Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol 2009; 27: 705–9.
- Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011; 59: 377–86.
- Hawthorn M.H., Chapple C.R., Cock M, Chess-Williams R. Urothelium - derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129: 416–9.
- Malone-Lee J.G., Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo - controlled study. BJU Int 2009; 103: 931–7.
- Chapple C.R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651–9.
- Раснер П.И., Пушкарь Д.Ю. Медикаментозная терапия у больных аденомой предстательной железы и гиперактивным мочевым пузырем. Cons. Med. 2011; 13 (7): 12–5.
- Witte L.P.W., Chapple C.R., de la Rosette J.J.M.C.H., Michel M.C. Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol 2008; 54: 326–34.
- Jumadilova Z, Harris H, del Aguilla M et al. Agent selection for overactive bladder patients with and without documented comorbid benign prostatic hyperplasia. Presented at: The 35th Annual Meeting of the International Continence Society; August 28–September 2, 2005. Montreal, Canada.
- Athanasopoulos A, Chapple C, Fowler C et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011; 60 (1): 94–105.
- Школьников М.Е. Спазмекс в лечении гиперактивного мочевого пузыря. Отечественный опыт применения. Урология. 2009; 6: 77–82.
- Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 2009; 43 (2): 283–95.
- Rovner E.S., Wein A.J. Once - daily, extended - release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002; 41: 6–14.
- Wiedemann A, Kusche W, Neumeister C. Flexible Dosing of Trospium Chloride for the Treatment of OAB – Results of a Non-Interventional Study in 4,092 Patients. Open Clin Trials J 2011; 3: 1–5.
- Bödeker R.H., Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12 - week, multicentre, double - blind, parallel - group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol 2010; 10: 15.
- Wiedemann A, Neumann G, Neumeister C et al. Efficacy and Tolerability of Add - On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Non - Interventional Trial Showing Use of Flexible Dosing. UroToday Int J 2009; 2 (2).
- Мазо Е.Б., Кривобородов Г.Г., Козырев С.В. и др. Троспиум хлорид в лечении идиопатической и нейрогенной детрузорной гиперактивности. Урология. 2005; 4: 56–9.
- Mac Diarmid S.A., Ellsworth P.I., Ginsberg D.A. et al. Safety and efficacy of once - daily trospium chloride extended - release in male patients with overactive bladder. Urology 2011; 77 (1): 24–9.
Supplementary files
